{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T23:51:28Z","timestamp":1790898688075,"version":"4.1.0"},"reference-count":67,"publisher":"Impact Journals, LLC","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncotarget"],"published-print":{"date-parts":[[2015,2,10]]},"DOI":"10.18632\/oncotarget.2992","type":"journal-article","created":{"date-parts":[[2015,9,15]],"date-time":"2015-09-15T08:01:01Z","timestamp":1442304061000},"page":"2088-2100","source":"Crossref","is-referenced-by-count":34,"title":["mTOR kinase inhibitors synergize with histone deacetylase inhibitors to kill B-cell acute lymphoblastic leukemia cells"],"prefix":"10.18632","volume":"6","author":[{"given":"Brandon R.","family":"Beagle","sequence":"first","affiliation":[{"name":"Department of Molecular Biology & Biochemistry, University of California, Irvine, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Duc M.","family":"Nguyen","sequence":"additional","affiliation":[{"name":"Department of Molecular Biology & Biochemistry, University of California, Irvine, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharmila","family":"Mallya","sequence":"additional","affiliation":[{"name":"Department of Molecular Biology & Biochemistry, University of California, Irvine, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah S.","family":"Tang","sequence":"additional","affiliation":[{"name":"Department of Molecular Biology & Biochemistry, University of California, Irvine, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengrou","family":"Lu","sequence":"additional","affiliation":[{"name":"Department of Molecular Biology & Biochemistry, University of California, Irvine, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhihong","family":"Zeng","sequence":"additional","affiliation":[{"name":"Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX"},{"name":"Department of Stem Cell Transplantation and Cellular Therapy, University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Konopleva","sequence":"additional","affiliation":[{"name":"Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX"},{"name":"Department of Stem Cell Transplantation and Cellular Therapy, University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thanh-Trang","family":"Vo","sequence":"additional","affiliation":[{"name":"Department of Molecular Biology & Biochemistry, University of California, Irvine, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David A.","family":"Fruman","sequence":"additional","affiliation":[{"name":"Department of Molecular Biology & Biochemistry, University of California, Irvine, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"7892","published-online":{"date-parts":[[2014,12,12]]},"reference":[{"issue":"6","key":"1","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1182\/blood-2012-05-378943","article-title":"Pediatric acute lymphoblastic leukemia: where are we going and how do we get there?","volume":"120","author":"Relling","year":"2012","journal-title":"Blood"},{"issue":"9617","key":"2","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1016\/S0140-6736(08)60457-2","article-title":"Acute lymphoblastic leukaemia","volume":"371","author":"Look","year":"2008","journal-title":"Lancet"},{"issue":"3","key":"3","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1182\/blood-2012-04-422691","article-title":"Tyrosine kinome sequencing of pediatric acute lymphoblastic leukemia: a report from the Children's Oncology Group TARGET Project","volume":"121","author":"Devidas","year":"2013","journal-title":"Blood"},{"issue":"11","key":"4","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1056\/NEJMoa1403088","article-title":"Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia","volume":"371","author":"Cheng","year":"2014","journal-title":"N Engl J Med"},{"issue":"2","key":"5","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.ccr.2012.06.005","article-title":"Genetic alterations activating kinase and cytokine receptor signaling in high-risk acute lymphoblastic leukemia","volume":"22","author":"Teachey","year":"2012","journal-title":"Cancer Cell"},{"issue":"2","key":"6","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.ccr.2010.11.014","article-title":"Early relapse in ALL is identified by time to leukemia in NOD\/SCID mice and is characterized by a gene signature involving survival pathways","volume":"19","author":"Stahnke","year":"2011","journal-title":"Cancer Cell"},{"issue":"4","key":"7","doi-asserted-by":"crossref","first-page":"e59335","DOI":"10.1371\/journal.pone.0059335","article-title":"Mammalian target of rapamycin (mTOR) activity dependent phospho-protein expression in childhood acute lymphoblastic leukemia (ALL)","volume":"8","author":"Csoka","year":"2013","journal-title":"PLoS ONE"},{"issue":"2","key":"8","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.cell.2012.03.017","article-title":"mTOR signaling in growth control and disease","volume":"149","author":"Sabatini","year":"2012","journal-title":"Cell"},{"issue":"22","key":"9","doi-asserted-by":"crossref","first-page":"5374","DOI":"10.1158\/1078-0432.CCR-10-0480","article-title":"Target of rapamycin signaling in leukemia and lymphoma","volume":"16","author":"Fruman","year":"2010","journal-title":"Clin Cancer Res"},{"issue":"12","key":"10","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1016\/j.tibs.2009.09.004","article-title":"TOR complex 2: a signaling pathway of its own","volume":"34","author":"Hall","year":"2009","journal-title":"Trends Biochem Sci"},{"issue":"6035","key":"11","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1126\/science.1199498","article-title":"The mTOR-regulated phosphoproteome reveals a mechanism of mTORC1-mediated inhibition of growth factor signaling","volume":"332","author":"Sabatini","year":"2011","journal-title":"Science"},{"issue":"6144","key":"12","doi-asserted-by":"crossref","first-page":"1236566","DOI":"10.1126\/science.1236566","article-title":"mTORC1 phosphorylation sites encode their sensitivity to starvation and rapamycin","volume":"341","author":"Sabatini","year":"2013","journal-title":"Science"},{"issue":"6035","key":"13","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1126\/science.1199484","article-title":"Phosphoproteomic analysis identifies Grb10 as an mTORC1 substrate that negatively regulates insulin signaling","volume":"332","author":"Blenis","year":"2011","journal-title":"Science"},{"issue":"2","key":"14","first-page":"e38","article-title":"Active-site inhibitors of mTOR target rapamycin-resistant outputs of mTORC1 and mTORC2","volume":"7","author":"Shokat","year":"2009","journal-title":"PLoS Biol"},{"issue":"12","key":"15","doi-asserted-by":"crossref","first-page":"8023","DOI":"10.1074\/jbc.M900301200","article-title":"An ATP-competitive mammalian target of rapamycin inhibitor reveals rapamycin-resistant functions of mTORC1","volume":"284","author":"Gray","year":"2009","journal-title":"J Biol Chem"},{"issue":"6","key":"16","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1016\/j.ceb.2011.09.003","article-title":"mTOR signaling in disease","volume":"23","author":"Hall","year":"2011","journal-title":"Curr Opin Cell Biol"},{"issue":"1","key":"17","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.ccr.2007.05.008","article-title":"Defining the role of mTOR in cancer","volume":"12","author":"Sabatini","year":"2007","journal-title":"Cancer Cell"},{"issue":"4","key":"18","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1038\/nrc2824","article-title":"Translational control in cancer","volume":"10","author":"Schneider","year":"2010","journal-title":"Nat Rev Cancer"},{"issue":"2","key":"19","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.ccr.2008.12.017","article-title":"mTOR complex 2 is required for the development of prostate cancer induced by Pten loss in mice","volume":"15","author":"Sabatini","year":"2009","journal-title":"Cancer Cell"},{"issue":"55","key":"20","first-page":"ra2","article-title":"Differential requirement of mTOR in postmitotic tissues and tumorigenesis","volume":"2","author":"Pandolfi","year":"2009","journal-title":"Sci Signal"},{"issue":"11","key":"21","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1038\/nrd3531","article-title":"Rapamycin passes the torch: a new generation of mTOR inhibitors","volume":"10","author":"Hall","year":"2011","journal-title":"Nat Rev Drug Discov"},{"key":"22","doi-asserted-by":"crossref","first-page":"69","DOI":"10.18632\/oncotarget.110","article-title":"Targeting TOR dependence in cancer","volume":"1","author":"Fruman","year":"2010","journal-title":"Oncotarget"},{"issue":"4","key":"23","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1172\/JCI44145","article-title":"Next-generation mTOR inhibitors in clinical oncology: how pathway complexity informs therapeutic strategy","volume":"121","author":"Slingerland","year":"2011","journal-title":"J Clin Invest"},{"issue":"6","key":"24","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1056\/NEJMoa1109653","article-title":"Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer","volume":"366","author":"Bachelot","year":"2012","journal-title":"N Engl J Med"},{"issue":"2","key":"25","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1038\/nrd4204","article-title":"PI3K and cancer: lessons, challenges, and opportunities","volume":"13","author":"Rommel","year":"2014","journal-title":"Nat Rev Drug Discov"},{"issue":"9","key":"26","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1158\/1078-0432.CCR-11-2750","article-title":"Dual mTORC1\/2 and HER2 blockade results in antitumor activity in preclinical models of breast cancer resistant to anti-HER2 therapy","volume":"18","author":"Scaltriti","year":"2012","journal-title":"Clin Cancer Res"},{"issue":"2","key":"27","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1038\/nm.2091","article-title":"Effective and selective targeting of leukemia cells using a TORC1\/2 kinase inhibitor","volume":"16","author":"Fruman","year":"2010","journal-title":"Nat Med"},{"issue":"3","key":"28","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1038\/leu.2012.276","article-title":"Efficacy of the investigational mTOR kinase inhibitor MLN0128\/INK128 in models of B-cell acute lymphoblastic leukemia","volume":"27","author":"Fruman","year":"2013","journal-title":"Leukemia"},{"issue":"8","key":"29","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1038\/leu.2012.60","article-title":"CREBBP HAT domain mutations prevail in relapse cases of high hyperdiploid childhood acute lymphoblastic leukemia","volume":"26","author":"Panzer-Grumayer","year":"2012","journal-title":"Leukemia"},{"issue":"7337","key":"30","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1038\/nature09727","article-title":"CREBBP mutations in relapsed acute lymphoblastic leukaemia","volume":"471","author":"Downing","year":"2011","journal-title":"Nature"},{"issue":"28 Suppl 1","key":"31","first-page":"S58","article-title":"Targeting histone deacetyalses in the treatment of B- and T-cell malignancies","author":"O'Connor","year":"2010","journal-title":"Invest New Drugs"},{"issue":"12","key":"32","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1038\/leu.2008.243","article-title":"Blockade of mTOR signaling potentiates the ability of histone deacetylase inhibitor to induce growth arrest and differentiation of acute myelogenous leukemia cells","volume":"22","author":"Yokoyama","year":"2008","journal-title":"Leukemia"},{"issue":"1","key":"33","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.jhep.2011.07.013","article-title":"Dual targeting of mTORC1\/C2 complexes enhances histone deacetylase inhibitor-mediated anti-tumor efficacy in primary HCC cancerand","volume":"56","author":"Yu","year":"2012","journal-title":"J Hepatol"},{"issue":"24","key":"34","doi-asserted-by":"crossref","first-page":"6882","DOI":"10.1158\/1078-0432.CCR-13-1906","article-title":"Phase I study of panobinostat plus everolimus in patients with relapsed or refractory lymphoma","volume":"19","author":"Younes","year":"2013","journal-title":"Clin Cancer Res"},{"issue":"268","key":"35","first-page":"ra20","article-title":"PUMA and BIM are required for oncogene inactivation-induced apoptosis","volume":"6","author":"Cheng","year":"2013","journal-title":"Sci Signal"},{"issue":"28","key":"36","doi-asserted-by":"crossref","first-page":"12469","DOI":"10.1073\/pnas.1005114107","article-title":"Critical roles for mTORC2- and rapamycin-insensitive mTORC1-complexes in growth and survival of BCR-ABL-expressing leukemic cells","volume":"107","author":"Platanias","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"9","key":"37","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1038\/nrd2133","article-title":"Anticancer activities of histone deacetylase inhibitors","volume":"5","author":"Johnstone","year":"2006","journal-title":"Nat Rev Drug Discov"},{"issue":"2","key":"38","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.blre.2010.01.001","article-title":"Novel agents for B-cell non-Hodgkin lymphoma: science and the promise","volume":"24","author":"Wilson","year":"2010","journal-title":"Blood Rev"},{"issue":"32","key":"39","doi-asserted-by":"crossref","first-page":"5459","DOI":"10.1200\/JCO.2009.22.1291","article-title":"Histone deacetylase inhibitors in cancer therapy","volume":"27","author":"Chabner","year":"2009","journal-title":"J Clin Oncol"},{"issue":"14","key":"40","doi-asserted-by":"crossref","first-page":"1911","DOI":"10.2165\/11315680-000000000-00000","article-title":"Histone deacetylase inhibitors: current status and overview of recent clinical trials","volume":"69","author":"Diasio","year":"2009","journal-title":"Drugs"},{"issue":"3","key":"41","first-page":"228","article-title":"Cancer epigenetics and targeted therapies","volume":"25","author":"Tycko","year":"2011","journal-title":"Oncology"},{"issue":"11","key":"42","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.2174\/092986711795471284","article-title":"Developing histone deacetylase inhibitors as anti-cancer therapeutics","volume":"18","author":"Evans","year":"2011","journal-title":"Curr Med Chem"},{"issue":"4","key":"43","first-page":"419","article-title":"Use of a novel histone deacetylase inhibitor to induce apoptosis in cell lines of acute lymphoblastic leukemia","volume":"89","author":"Ottmann","year":"2004","journal-title":"Haematologica"},{"issue":"12","key":"44","doi-asserted-by":"crossref","first-page":"3069","DOI":"10.1158\/0008-5472.CAN-11-4106","article-title":"Mcl-1 Phosphorylation defines ABT-737 resistance that can be overcome by increased NOXA expression in leukemic B cells","volume":"72","author":"Almasan","year":"2012","journal-title":"Cancer Res"},{"issue":"2","key":"45","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.cell.2006.12.029","article-title":"FoxOs are lineage-restricted redundant tumor suppressors and regulate endothelial cell homeostasis","volume":"128","author":"DePinho","year":"2007","journal-title":"Cell"},{"issue":"16","key":"46","doi-asserted-by":"crossref","first-page":"2276","DOI":"10.1038\/onc.2008.21","article-title":"The FoxO code","volume":"27","author":"Brunet","year":"2008","journal-title":"Oncogene"},{"issue":"16","key":"47","doi-asserted-by":"crossref","first-page":"2258","DOI":"10.1038\/onc.2008.29","article-title":"A brief introduction to FOXOlogy","volume":"27","author":"Burgering","year":"2008","journal-title":"Oncogene"},{"issue":"2","key":"48","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1038\/nrm3507","article-title":"FOXOs: signalling integrators for homeostasis maintenance","volume":"14","author":"Burgering","year":"2013","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"6","key":"49","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1016\/j.devcel.2006.10.007","article-title":"Ablation in mice of the mTORC components raptor, rictor, or mLST8 reveals that mTORC2 is required for signaling to Akt-FOXO and PKCalpha, but not S6K1","volume":"11","author":"Sabatini","year":"2006","journal-title":"Dev Cell"},{"issue":"1","key":"50","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.cell.2006.08.033","article-title":"SIN1\/MIP1 maintains rictor-mTOR complex integrity and regulates Akt phosphorylation and substrate specificity","volume":"127","author":"Su","year":"2006","journal-title":"Cell"},{"issue":"7281","key":"51","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1038\/nature08734","article-title":"TGF-beta-FOXO signalling maintains leukaemia-initiating cells in chronic myeloid leukaemia","volume":"463","author":"Hirao","year":"2010","journal-title":"Nature"},{"issue":"14","key":"52","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1038\/sj.onc.1208421","article-title":"Direct transcriptional regulation of Bim by FoxO3a mediates STI571-induced apoptosis in Bcr-Abl-expressing cells","volume":"24","author":"Lam","year":"2005","journal-title":"Oncogene"},{"issue":"8","key":"53","doi-asserted-by":"crossref","first-page":"6411","DOI":"10.1074\/jbc.M211562200","article-title":"A Member of Forkhead Transcription Factor FKHRL1 Is a Downstream Effector of STI571-induced Cell Cycle Arrest in BCR-ABL-expressing Cells","volume":"278","author":"Ozawa","year":"2003","journal-title":"J Biol Chem"},{"issue":"3","key":"54","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1007\/s00109-011-0726-6","article-title":"mTOR links oncogenic signaling to tumor cell metabolism","volume":"89","author":"Manning","year":"2011","journal-title":"J Mol Med"},{"key":"55","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1186\/1756-8722-6-53","article-title":"Histone deacetylase inhibitor potentiated the ability of MTOR inhibitor to induce autophagic cell death in Burkitt leukemia\/lymphoma","volume":"6","author":"Zhao","year":"2013","journal-title":"J Hematol Oncol"},{"issue":"14","key":"56","doi-asserted-by":"crossref","first-page":"2926","DOI":"10.1182\/blood-2009-05-220889","article-title":"Inhibition of histone deacetylase overcomes rapamycin-mediated resistance in diffuse large B-cell lymphoma by inhibiting Akt signaling through mTORC2","volume":"114","author":"Witzig","year":"2009","journal-title":"Blood"},{"issue":"15","key":"57","doi-asserted-by":"crossref","first-page":"4104","DOI":"10.1158\/1078-0432.CCR-12-0055","article-title":"Cancer network disruption by a single molecule inhibitor targeting both histone deacetylase activity and phosphatidylinositol 3-kinase signaling","volume":"18","author":"Cai","year":"2012","journal-title":"Clin Cancer Res"},{"issue":"2","key":"58","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.molonc.2013.11.007","article-title":"TORC1 and class I HDAC inhibitors synergize to suppress mature B cell neoplasms","volume":"8","author":"Mock","year":"2014","journal-title":"Mol Oncol"},{"issue":"18","key":"59","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1200\/JCO.2011.38.1350","article-title":"Panobinostat in patients with relapsed\/refractory Hodgkin's lymphoma after autologous stem-cell transplantation: results of a phase II study","volume":"30","author":"Engert","year":"2012","journal-title":"J Clin Oncol"},{"issue":"2","key":"60","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1002\/ajh.22231","article-title":"Inhibition of cell-mediated immunity by the histone deacetylase inhibitor vorinostat: implications for therapy of cutaneous T-cell lymphoma","volume":"87","author":"Rook","year":"2012","journal-title":"Am J Hematol"},{"issue":"7","key":"61","doi-asserted-by":"crossref","first-page":"e11821","DOI":"10.1371\/journal.pone.0011821","article-title":"Differential modulation of TCF\/LEF-1 activity by the soluble LRP6-ICD","volume":"5","author":"Johnson","year":"2010","journal-title":"PLoS ONE"},{"issue":"7347","key":"62","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1038\/nature09883","article-title":"BCL6 enables Ph+ acute lymphoblastic leukaemia cells to survive BCR-ABL1 kinase inhibition","volume":"473","author":"Koeffler","year":"2011","journal-title":"Nature"},{"issue":"10","key":"63","doi-asserted-by":"crossref","first-page":"e13375","DOI":"10.1371\/journal.pone.0013375","article-title":"Novel HTS strategy identifies TRAIL-sensitizing compounds acting specifically through the caspase-8 apoptotic axis","volume":"5","author":"Vuori","year":"2010","journal-title":"PLoS ONE"},{"key":"64","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1476-4598-11-1","article-title":"Systems-wide RNAi analysis of CASP8AP2\/FLASH shows transcriptional deregulation of the replication-dependent histone genes and extensive effects on the transcriptome of colorectal cancer cells","volume":"11","author":"Caplen","year":"2012","journal-title":"Mol Cancer"},{"key":"65","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1186\/1476-4598-10-95","article-title":"Essential role of caspase-8 in p53\/p73-dependent apoptosis induced by etoposide in head and neck carcinoma cells","volume":"10","author":"Ikeda","year":"2011","journal-title":"Mol Cancer"},{"issue":"2","key":"66","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.cell.2012.08.038","article-title":"Relative mitochondrial priming of myeloblasts and normal HSCs determines chemotherapeutic success in AML","volume":"151","author":"Letai","year":"2012","journal-title":"Cell"},{"issue":"2","key":"67","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1158\/0008-5472.CAN-09-1947","article-title":"Drug combination studies and their synergy quantification using the Chou-Talalay method","volume":"70","author":"Chou","year":"2010","journal-title":"Cancer Res"}],"container-title":["Oncotarget"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.2992","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,8]],"date-time":"2020-09-08T09:41:23Z","timestamp":1599558083000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.2992"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,12,12]]},"references-count":67,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2015,2,10]]}},"alternative-id":["2992","25576920"],"URL":"https:\/\/doi.org\/10.18632\/oncotarget.2992","relation":{},"ISSN":["1949-2553"],"issn-type":[{"value":"1949-2553","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,12,12]]}}}